{"id":"https://openalex.org/W4365512263","doi":"https://doi.org/10.1158/1538-7445.am2023-ct197","title":"Abstract CT197: Profiling of tumor infiltrating T cells in malignant pleural/peritoneal mesothelioma (MPM) and ovarian cancer patients as part of a Phase 1 clinical trial of gavo-cel (TC-210)","display_name":"Abstract CT197: Profiling of tumor infiltrating T cells in malignant pleural/peritoneal mesothelioma (MPM) and ovarian cancer patients as part of a Phase 1 clinical trial of gavo-cel (TC-210)","publication_year":2023,"publication_date":"2023-04-14","ids":{"openalex":"https://openalex.org/W4365512263","doi":"https://doi.org/10.1158/1538-7445.am2023-ct197"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2023-ct197","doi":"https://doi.org/10.1158/1538-7445.am2023-ct197","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2023-ct197","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5052507426","display_name":"Munisha Smalley","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Munisha Smalley","raw_affiliation_strings":["1TCR2 Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1TCR2 Therapeutics, Inc., Cambridge, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075730499","display_name":"Michael Glenn Ross","orcid":"https://orcid.org/0000-0001-5500-404X","observed_orcids":["https://orcid.org/0000-0001-5500-404X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael Ross","raw_affiliation_strings":["1TCR2 Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1TCR2 Therapeutics, Inc., Cambridge, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041693781","display_name":"Samantha F. Fowler","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Samantha F. Fowler","raw_affiliation_strings":["1TCR2 Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1TCR2 Therapeutics, Inc., Cambridge, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Lauren McLaughlin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lauren McLaughlin","raw_affiliation_strings":["1TCR2 Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1TCR2 Therapeutics, Inc., Cambridge, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049355235","display_name":"Erin Jeter","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Erin Jeter","raw_affiliation_strings":["1TCR2 Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1TCR2 Therapeutics, Inc., Cambridge, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074613287","display_name":"Kevin Zikaras","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kevin Zikaras","raw_affiliation_strings":["1TCR2 Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1TCR2 Therapeutics, Inc., Cambridge, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002662528","display_name":"Philip D. Bardwell","orcid":"https://orcid.org/0000-0002-3835-255X","observed_orcids":["https://orcid.org/0000-0002-3835-255X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Philip D. Bardwell","raw_affiliation_strings":["1TCR2 Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1TCR2 Therapeutics, Inc., Cambridge, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107977581","display_name":"Alfonso Quint\u00e1s\u2010Cardama","orcid":"https://orcid.org/0000-0002-4623-8917","observed_orcids":["https://orcid.org/0000-0002-4623-8917"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alfonso Quint\u00e1s-Cardama","raw_affiliation_strings":["1TCR2 Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1TCR2 Therapeutics, Inc., Cambridge, MA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5023615653","display_name":"Robert Tighe","orcid":"https://orcid.org/0009-0005-8406-0709","observed_orcids":["https://orcid.org/0009-0005-8406-0709"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert Tighe","raw_affiliation_strings":["1TCR2 Therapeutics, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1TCR2 Therapeutics, Inc., Cambridge, MA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"83","issue":"8_Supplement","first_page":"CT197","last_page":"CT197"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.7261000275611877,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.7261000275611877,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.14869999885559082,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.04410000145435333,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/malignant-pleural-mesothelioma","display_name":"malignant pleural mesothelioma","score":0.8989999890327454},{"id":"https://openalex.org/keywords/ovarian-cancer","display_name":"ovarian cancer","score":0.925000011920929},{"id":"https://openalex.org/keywords/mesothelin","display_name":"mesothelin","score":0.9399999976158142},{"id":"https://openalex.org/keywords/adoptive-t-cell-therapy","display_name":"adoptive T cell therapy","score":0.7770000100135803},{"id":"https://openalex.org/keywords/tumor-infiltrating-lymphocytes","display_name":"tumor-infiltrating lymphocytes","score":0.8960000276565552},{"id":"https://openalex.org/keywords/cd8-t-cells","display_name":"CD8+ T cells","score":0.8579999804496765},{"id":"https://openalex.org/keywords/pd-l1","display_name":"PD-L1","score":0.652999997138977},{"id":"https://openalex.org/keywords/tumor-immune-contexture","display_name":"tumor immune contexture","score":0.7889999747276306},{"id":"https://openalex.org/keywords/immune-exclusion","display_name":"immune exclusion","score":0.7699999809265137},{"id":"https://openalex.org/keywords/tumor-infiltrating-macrophages","display_name":"tumor-infiltrating macrophages","score":0.6340000033378601},{"id":"https://openalex.org/keywords/tumor-associated-neutrophils","display_name":"tumor-associated neutrophils","score":0.6050000190734863},{"id":"https://openalex.org/keywords/multiplex-immunofluorescence","display_name":"multiplex immunofluorescence","score":0.7829999923706055}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8145530223846436},{"id":"https://openalex.org/C2777045440","wikidata":"https://www.wikidata.org/wiki/Q14914057","display_name":"Mesothelin","level":3,"score":0.5953075885772705},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5516841411590576},{"id":"https://openalex.org/C2780427987","wikidata":"https://www.wikidata.org/wiki/Q172341","display_name":"Ovarian cancer","level":3,"score":0.5453478693962097},{"id":"https://openalex.org/C167672396","wikidata":"https://www.wikidata.org/wiki/Q417800","display_name":"CD8","level":3,"score":0.4773145616054535},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.451101690530777},{"id":"https://openalex.org/C2777407522","wikidata":"https://www.wikidata.org/wiki/Q1077603","display_name":"Mesothelioma","level":2,"score":0.4364871680736542},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.42547863721847534},{"id":"https://openalex.org/C16930146","wikidata":"https://www.wikidata.org/wiki/Q4381253","display_name":"Stromal cell","level":2,"score":0.42402273416519165},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4047716557979584},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.38281065225601196},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.35006025433540344},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3268616497516632},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2813003659248352},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.256437212228775}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2023-ct197","doi":"https://doi.org/10.1158/1538-7445.am2023-ct197","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2023-ct197","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4379281047","https://openalex.org/W3180623118","https://openalex.org/W4385302690","https://openalex.org/W4308398756","https://openalex.org/W3204751795","https://openalex.org/W2890561829","https://openalex.org/W7117237932","https://openalex.org/W3179214161","https://openalex.org/W3183438601","https://openalex.org/W7221545450"],"abstract_inverted_index":{"Abstract":[0],"Gavocabtagene":[1],"autoleucel":[2],"(gavo-cel;":[3],"TC-210)":[4],"is":[5],"a":[6,37,76,189,194,216,219,239,275,291,401,506],"T":[7,132,163,198,224,243,281,295,431,464,492],"cell":[8,13,164,225,432],"receptor":[9],"fusion":[10],"construct":[11],"(TRuC)":[12],"therapy":[14],"directed":[15],"against":[16],"mesothelin.":[17],"As":[18],"part":[19,504],"of":[20,40,123,128,140,197,242,256,279,372,386,404,454,489,505,511,517],"the":[21,111,118,124,135,156,162,185,208,228,246,266,271,299,322,363,392,413,451,518],"phase":[22,120,418],"1":[23,52,508],"dose-escalation":[24],"clinical":[25,509],"trial":[26,510],"(NCT03907852),":[27],"patients":[28,43,148,170,235,268,286,334,367,502],"with":[29,44,104,188,207,215,236,287,302,310,335,361,368,395,407,426,436,461],"advanced":[30],"solid":[31],"tumors":[32],"expressing":[33],"mesothelin":[34],"were":[35],"administered":[36],"single":[38],"infusion":[39,261],"gavo-cel.":[41],"Thirty-two":[42],"late-stage":[45],"disease":[46,70,84],"(23":[47],"MPM,":[48],"8":[49,250,258],"ovarian":[50,288,500],"and":[51,106,137,174,317,342,378,434,447,457,499,531],"cholangiocarcinoma)":[53],"received":[54],"gavo-cel":[55,463,512],"at":[56,87,200,249,329],"doses":[57],"ranging":[58],"from":[59,168,326],"5":[60,64],"\u00d7":[61,65,98],"107":[62],"-":[63],"108":[66,99],"TRuC":[67,100],"cells/m2.":[68],"The":[69,254,307],"control":[71],"rate":[72],"(defined":[73],"as":[74,110,383,389,445,503],"achieving":[75],"response":[77,191],"by":[78],"RECISTv1.1":[79],"criteria":[80],"or":[81],"having":[82],"stable":[83],"[SD]":[85],"for":[86,117,321,521],"least":[88],"12":[89],"weeks":[90,176,251,259],"post-infusion)":[91],"was":[92,108,262],"77%.":[93],"Dose":[94,115],"level":[95],"3":[96],"(1":[97],"cells/m2":[101],"following":[102,359],"lymphodepletion":[103],"cyclophosphamide":[105],"fludarabine)":[107],"selected":[109],"Recommended":[112],"Phase":[113,507],"2":[114,121,233,528],"(RP2D)":[116],"ongoing":[119],"portion":[122],"trial.":[125],"Spatial":[126],"distribution":[127],"immune":[129,158,304,373,415,455],"cells,":[130,133],"particularly":[131],"in":[134,166,202,222,245,265,293,315,340,366,391,417,494],"tumor":[136,141,157,203,229,247,364,414,424,490],"stromal":[138],"regions":[139,365],"biopsies":[142,167,204],"has":[143],"been":[144],"shown":[145],"to":[146,152,173,270,399,428,449],"identify":[147],"that":[149,184],"may":[150],"respond":[151],"immunotherapies.":[153],"To":[154],"understand":[155],"contexture,":[159],"we":[160],"profiled":[161],"compartment":[165,248],"five":[169],"collected":[171],"prior":[172],"eight":[175],"post":[177,252,260],"treatment":[178,360],"using":[179],"multiplexed":[180],"immunofluorescence.":[181],"We":[182,409,438],"observed":[183],"MPM":[186,237,311,336,396],"patient":[187,214,309,394],"partial":[190],"(PR)":[192],"had":[193,218,238,290,312,337],"greater":[195],"number":[196,278,403],"cells":[199,244,296,456,493],"baseline":[201],"when":[205],"compared":[206,269],"other":[209],"SD":[210,234,267,285,333,369],"patients.":[211],"Notably,":[212],"this":[213,350],"PR,":[217],"3.6-fold":[220],"increase":[221,241,314],"CD3+CD8+":[223,294],"infiltrates":[226],"into":[227,298],"bed.":[230],"In":[231,348],"contrast,":[232],"minimal":[240,313],"infusion.":[253],"density":[255],"TILs":[257,356,405],"much":[263],"lower":[264],"PR":[272,308,393],"subject,":[273],"indicating":[274,344],"potentially":[276],"insufficient":[277],"infiltrating":[280,297,462,491],"cells.":[282,465],"Interestingly,":[283],"2/2":[284],"cancer":[289,501],"decrease":[292],"tumor,":[300],"consistent":[301],"an":[303],"exclusion":[305],"phenotype.":[306],"PD-L1":[316,341,377],"CD155":[318,379],"(a":[319],"ligand":[320],"inhibitory":[323],"receptor,":[324],"TIGIT)":[325],"negligible":[327],"levels":[328],"baseline,":[330],"whereas":[331],"both":[332],"marked":[338],"increases":[339],"CD155,":[343],"potential":[345],"resistance":[346],"mechanisms.":[347],"summary,":[349],"preliminary":[351],"data":[352],"suggests":[353],"although":[354],"CD8+":[355],"are":[357,410],"increased":[358],"gavo-cel,":[362],"show":[370],"evidence":[371],"surveillance":[374],"escape":[375],"via":[376],"upregulation,":[380],"thus":[381],"acting":[382],"putative":[384],"mechanisms":[385],"resistance.":[387],"However,":[388],"seen":[390],"there":[397],"appears":[398],"be":[400],"critical":[402],"associating":[406],"response.":[408,437],"currently":[411],"evaluating":[412],"contexture":[416],"2,":[419],"focusing":[420],"on":[421],"differences":[422],"across":[423],"types":[425],"regards":[427],"TIL":[429],"content,":[430],"influx,":[433],"correlations":[435],"will":[439],"also":[440],"explore":[441],"additional":[442],"markers":[443],"such":[444],"PD-1":[446],"TIGIT,":[448],"profile":[450],"exhaustion":[452],"state":[453],"their":[458],"spatial":[459],"relationship":[460],"Citation":[466],"Format:":[467],"Munisha":[468],"Smalley,":[469],"Michael":[470],"Ross,":[471],"Samantha":[472],"F.":[473],"Fowler,":[474],"Lauren":[475],"McLaughlin,":[476],"Erin":[477],"Jeter,":[478],"Kevin":[479],"Zikaras,":[480],"Philip":[481],"D.":[482],"Bardwell,":[483],"Alfonso":[484],"Quint\u00e1s-Cardama,":[485],"Robert":[486],"Tighe.":[487],"Profiling":[488],"malignant":[495],"pleural/peritoneal":[496],"mesothelioma":[497],"(MPM)":[498],"(TC-210)":[513],"[abstract].":[514],"In:":[515],"Proceedings":[516],"American":[519],"Association":[520],"Cancer":[522,542],"Research":[523],"Annual":[524],"Meeting":[525],"2023;":[526],"Part":[527],"(Clinical":[529],"Trials":[530],"Late-Breaking":[532],"Research);":[533],"2023":[534],"Apr":[535],"14-19;":[536],"Orlando,":[537],"FL.":[538],"Philadelphia":[539],"(PA):":[540],"AACR;":[541],"Res":[543],"2023;83(8_Suppl):Abstract":[544],"nr":[545],"CT197.":[546]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":1}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2023-04-15T00:00:00"}